SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03548064

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase 1 Double-Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Oral, Sublingual, or Intradermal Vaccination in Adults Residing in an Endemic Area

This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135 healthy adult volunteers, age 18-45 years. Study duration is approximately 2.5 years, with each participant duration for up to 9 months depending on the route of dmLT administered. There is no specific hypothesis being tested in this study. The primary objective of this study is to assess the reactogenicity, safety, and tolerability of dmLT when administered in three sequential doses, over a range of dosages by oral, sublingual, or intradermal routes.

NCT03548064 Gastroenteritis Escherichia Coli Immunisation
MeSH: Gastroenteritis

6 Interventions

Name: Placebo

Description: Placebo

Type: Other

Regimen A Regimen B Regimen G

Name: Placebo

Description: Placebo

Type: Other

Regimen C Regimen D Regimen H

Name: Placebo

Description: Placebo

Type: Other

Regimen E Regimen F Regimen I

Name: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.

Type: Biological

Regimen A Regimen B Regimen G

Name: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.

Type: Biological

Regimen C Regimen D Regimen H

Name: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine

Description: LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at amino acid position 192 with glycine and the leucine at amino acid position 211 with alanine. These two amino acid substitutions take place in proteolytic cleavage sites which are critical for activation of the secreted toxin molecules.

Type: Biological

Regimen E Regimen F Regimen I


Primary Outcomes

Measure: The occurrence of discontinuation of study vaccination

Time: Day 1 up to day 223

Measure: The occurrence of solicited local site events

Time: Day 1 to day 8

Measure: The occurrence of solicited local site events

Time: Day 15 to day 36

Measure: The occurrence of solicited local site events

Time: Day 43 to day 50

Measure: The occurrence of study withdrawals

Time: Day 1 up to day 223

Measure: The occurrence of systemic reactogenicity events

Time: Day 1 to day 8

Measure: The occurrence of systemic reactogenicity events

Time: Day 15 to day 36

Measure: The occurrence of systemic reactogenicity events

Time: Day 43 to day 50

Measure: The occurrence of unsolicited vaccine-related adverse events (AE), including laboratory AE

Time: Day 1 to day 71

Secondary Outcomes

Measure: The occurrence of vaccine-related serious adverse events (SAE)

Time: Day 1 up to day 223

Measure: The proportion of participants with = / > 2-fold rise in ALS anti-dmLT-specific IgA titers over baseline measured by ELISA

Time: Day 1 to day 114

Measure: The proportion of participants with = / > 2-fold rise in ALS anti-dmLT-specific IgG titers over baseline measured by ELISA

Time: Day 1 to day 114

Measure: The proportion of participants with >8 dmLT-specific IgA or IgG ASC / 10^6 PBMC as measured by ELISpot

Time: Day 1 to day 114

Measure: The proportion of participants with a = / > 4-fold rise in dmLT-specific serum IgA titers over baseline measured by ELISA

Time: Day 1 to day 114

Measure: The proportion of participants with a = / > 4-fold rise in dmLT-specific serum IgG titers over baseline measured by ELISA

Time: Day 1 to day 114

Measure: The proportion of participants with a = / > 4-fold rise over baseline in dmLT-specific fecal IgA titers measured by ELISA

Time: Day 1 to day 57

Measure: The proportion of participants with a = / > 4-fold rise over baseline in dmLT-specific salivary IgA titers measured by ELISA

Time: Day 1 to day 57

Purpose: Prevention

Allocation: Randomized

Sequential Assignment


There is one SNP

SNPs


1 L211A

A Phase 1 Double-Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Immunogenicity of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Oral, Sublingual, or Intradermal Vaccination in Adults Residing in an Endemic Area. --- L211A ---

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135 healthy adult volunteers, age 18-45 years. --- L211A ---

Gastroenteritis Escherichia Coli Immunisation Gastroenteritis This is a Phase 1 double-blinded, placebo-controlled, dose-escalation trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135 healthy adult volunteers, age 18-45 years, who meet all the eligibility criteria and reside in Bangladesh. --- L211A ---



HPO Nodes